Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction.
The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
A Response to: Letter to the Editor Regarding “Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: a Narrative Review.
EPA levels and cardiovascular outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial.
Eicosapentaenoic acid inhibits membrane lipid oxidation in a concentration-dependent manner at pharmacologic doses in vitro
Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro.
Icosapent ethyl effects on fatty acid profiles in statin-treated patients with high triglycerides: the randomized, placebo-controlled ANCHOR study
Effects of AMR101, a pure eicosapentaenoic omega-3 fatty acid, on the fatty acid profile in plasma and red blood cells in statin-treated patients with persistent high triglycerides (results from the ANCHOR study)
The triglyceride-lowering effects of icosapent ethyl (pure eicosapentaenoic acid ethyl ester) correlate with reductions in ASCVD risk factors commonly found in hypertriglyceridemic patients.
Eicosapentaenoic acid inhibits membrane cholesterol domains compared to other omega-3 fatty acids under conditions of hyperglycemia [abstract 005].
Omega-3 fatty acid eicosapentaenoic acid (EPA), but not docosahexaenoic acid (DHA), improved nitric oxide bioavailability in human endothelial cells [abstract 007].
Icosapent ethyl: eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies.
Icosapent ethyl, a pure EPA omega-3 fatty acid: Effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study).
Eicosapentaenoic acid inhibited oxidized HDL-induced loss of endothelial nitric oxide release as compared to fenofibrate or niacin in vitro
Eicosapentaenoic acid (EPA) inhibits human low-density lipoprotein oxidation in a concentration- and time-dependent manner at pharmacologic doses in vitro [abstract EAS19-0568].
Eicosapentaenoic acid (EPA) containing phospholipids modulate membrane structure.
Comparing eicosapentaenoic acid between plasma and serum from a randomized, controlled clinical trial
Effects of icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, on the fatty acid profile in plasma and red blood cells in statin-treated patients with persistent high triglycerides (results from the ANCHOR study)
Eicosapentaenoic acid is a strong predictor of risk for heart failure in the multi-ethnic study of atherosclerosis
Plasma EPA (eicosapentaenoic acid)/AA (arachidonic acid) ratio in patients with stage 5 chronic kidney disease: a novel, treatable target